MCID: OVR042
MIFTS: 76

Ovarian Cancer malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

Aliases & Descriptions for Ovarian Cancer:

Name: Ovarian Cancer 12 50 25 52 41 3 14
Ovarian Carcinoma 12 50 25 29 13 52 14 69
Malignant Neoplasm of the Ovary 25 29
Ovarian Neoplasm 12 69
Primary Malignant Neoplasm of Ovary 69
Ovarian Cancer, Susceptibility to 13
Malignant Tumor of the Ovary 25
Malignant Neoplasm of Ovary 69
Malignant Tumour of Ovary 12
Ovarian Epithelial Cancer 42
Epithelial Ovarian Cancer 69
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 25
Tumor of the Ovary 12
Ovarian Neoplasms 42
Ovary Neoplasm 12

Classifications:



Summaries for Ovarian Cancer

NIH Rare Diseases : 50 ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. many people with early ovarian cancer have no signs or symptoms of the condition. when present, symptoms are often nonspecific and blamed on other, more common conditions. most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as brca1 or brca2 hereditary breast and ovarian cancer syndrome, lynch syndrome and peutz-jeghers syndrome) and are inherited in an autosomal dominant manner. the best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy). last updated: 3/30/2015

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to peritoneal mesothelioma and colorectal cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and testes, and related phenotypes are Decreased viability and cellular

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Genetics Home Reference : 25 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

MedlinePlus : 41 the ovaries are part of the female reproductive system. they produce a woman's eggs and female hormones. each ovary is about the size and shape of an almond. cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. the sooner ovarian cancer is found and treated, the better your chance for recovery. but ovarian cancer is hard to detect early. women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. then it is hard to treat. symptoms may include a heavy feeling in the pelvis pain in the lower abdomen bleeding from the vagina weight gain or loss abnormal periods unexplained back pain that gets worse gas, nausea, vomiting, or loss of appetite to diagnose ovarian cancer, doctors do one or more tests. they include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. treatment is usually surgery followed by chemotherapy. nih: national cancer institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Novus Biologicals : 53 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

Wikipedia : 71 Ovarian cancer is a cancer that forms in an ovary. It results in abnormal cells that have the ability to... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
id Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 30.0 CDH1 CTNNB1 KRAS PIK3CA TP53
2 colorectal cancer 29.8 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 EGFR
3 porokeratosis 29.7 MUC1 PGR TP53
4 glioma 29.7 ERBB2 PGR
5 hereditary breast ovarian cancer 12.3
6 ovarian cancer, somatic 12.2
7 childhood ovarian cancer 12.1
8 brca1 hereditary breast and ovarian cancer syndrome 12.1
9 brca2 hereditary breast and ovarian cancer syndrome 12.1
10 breast-ovarian cancer, familial 4 12.1
11 breast-ovarian cancer, familial 3 12.1
12 breast-ovarian cancer, familial, 1 12.1
13 breast-ovarian cancer, familial, 2 12.1
14 brca1 and brca2 hereditary breast and ovarian cancer 11.8
15 hereditary site-specific ovarian cancer syndrome 11.7
16 rad51c-related familial susceptibility to breast-ovarian cancer 11.7
17 rad51d-related familial susceptibility to breast-ovarian cancer 11.7
18 brca1- and brca2-associated hereditary breast and ovarian cancer 11.7
19 familiar ovarian carcinoma 11.7
20 pancreatic cancer 11.3
21 paraneoplastic cerebellar degeneration 11.2
22 breast cancer 11.2
23 lynch syndrome 11.1
24 ovarian disease 11.1
25 ovarian epithelial cancer 11.0
26 ovarian small cell carcinoma 10.9
27 ovarian melanoma 10.7
28 ovarian clear cell carcinoma 10.7
29 ovary epithelial cancer 10.7
30 granulosa cell tumor of the ovary 10.7
31 aorto-ventricular tunnel 10.5 BRCA1 BRCA2
32 kunjin encephalitis 10.5 BRCA1 BRCA2 ERBB2
33 pineal region mature teratoma 10.4 EGFR ERBB2
34 cyanide-induced parkinsonism 10.4 CDH1 MUC16
35 linitis plastica 10.4 CDH1 TP53
36 peritonitis 10.4
37 lung clear cell-sugar-tumor 10.4 BRCA1 BRCA2 ERBB2 TP53
38 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 10.4 BRCA2 PIK3CA
39 mediastinum synovial sarcoma 10.4 BRCA1 BRCA2 PIK3CA TP53
40 bladder colloid adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2 TP53
41 submucosal invasive colon adenocarcinoma 10.4 BRCA2 CTNNB1 TP53
42 mycobacterium kansasii 10.4 BRCA1 BRCA2 TP53
43 penis paget's disease 10.4 MUC1 PIK3CA
44 endotheliitis 10.4
45 ovarian cystadenocarcinoma 10.4 EGFR ERBB2 VEGFA
46 multicentric papillary thyroid carcinoma 10.4 CTNNB1 EGFR TP53
47 cellular ependymoma 10.4 BRCA1 BRCA2 MUC1 TP53
48 nasal cavity adenocarcinoma 10.4 BRCA2 ERBB2 MUC1
49 wolffian adnexal neoplasm 10.4 EGFR TP53
50 nodular cutaneous amyloidosis 10.4 CDH1 CTNNB1 TP53

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.15 EGFR KRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 10.15 KRAS ERBB3
3 Decreased viability GR00221-A-1 10.15 KRAS PIK3CA CDH1 EGFR
4 Decreased viability GR00221-A-2 10.15 KRAS PIK3CA BRCA1 ERBB3
5 Decreased viability GR00221-A-3 10.15 BRCA1
6 Decreased viability GR00221-A-4 10.15 EGFR PIK3CA ERBB3
7 Decreased viability GR00301-A 10.15 KRAS BRCA1 CDH1 ERBB3
8 Decreased viability GR00342-S-2 10.15 ERBB3
9 Decreased viability GR00342-S-3 10.15 ERBB3
10 Decreased viability GR00381-A-1 10.15 KRAS
11 Decreased cell migration GR00055-A-1 9.65 CTNNB1 EGFR KRAS MUC1 PIK3CA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CTNNB1 EGFR ERBB2 MUC1 VEGFA
13 Increased cell death HMECs cells GR00103-A-0 9.17 BRCA1 CTNNB1 EGFR ERBB3 PGR PIK3CA

MGI Mouse Phenotypes related to Ovarian Cancer:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 ERBB3 FOLR1 GPR68 KRAS PGR PIK3CA
2 homeostasis/metabolism MP:0005376 10.5 KRAS PGR PIK3CA TP53 VEGFA FOLR1
3 embryo MP:0005380 10.48 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 DPH1
4 endocrine/exocrine gland MP:0005379 10.47 ERBB2 ERBB3 FOLR1 GPR68 KRAS PGR
5 cardiovascular system MP:0005385 10.44 CDKN1A CTNNB1 BRCA1 CDH1 EGFR ERBB2
6 growth/size/body region MP:0005378 10.44 CDKN1A CTNNB1 DPH1 EGFR ERBB2 ERBB3
7 digestive/alimentary MP:0005381 10.42 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 DPH1
8 behavior/neurological MP:0005386 10.41 BRCA1 BRCA2 CDKN1A CTNNB1 ERBB2 ERBB3
9 mortality/aging MP:0010768 10.41 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 DPH1
10 integument MP:0010771 10.39 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 DPH1
11 neoplasm MP:0002006 10.38 ERBB3 FOLR1 GPR68 KRAS PGR PIK3CA
12 immune system MP:0005387 10.37 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 EGFR
13 hematopoietic system MP:0005397 10.32 GPR68 KRAS PGR TP53 VEGFA BRCA1
14 nervous system MP:0003631 10.3 EGFR ERBB2 ERBB3 FOLR1 KLK8 KRAS
15 limbs/digits/tail MP:0005371 10.28 BRCA1 BRCA2 CDKN1A CTNNB1 DPH1 EGFR
16 craniofacial MP:0005382 10.27 CDKN1A CTNNB1 DPH1 EGFR ERBB2 FOLR1
17 muscle MP:0005369 10.24 BRCA1 CDKN1A CTNNB1 EGFR ERBB2 ERBB3
18 normal MP:0002873 10.18 BRCA1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
19 no phenotypic analysis MP:0003012 10.09 VEGFA CDH1 CDKN1A CTNNB1 EGFR KRAS
20 liver/biliary system MP:0005370 10.07 CDKN1A CTNNB1 DPH1 EGFR KRAS TP53
21 hearing/vestibular/ear MP:0005377 10.06 CDKN1A CTNNB1 EGFR FOLR1 KRAS TP53
22 reproductive system MP:0005389 10.03 BRCA1 BRCA2 CDH1 CDKN1A CTNNB1 EGFR
23 renal/urinary system MP:0005367 9.97 BRCA1 CDKN1A CTNNB1 EGFR FOLR1 GPR68
24 pigmentation MP:0001186 9.91 ERBB3 BRCA1 CTNNB1 DPH1 EGFR KRAS
25 respiratory system MP:0005388 9.9 KRAS TP53 VEGFA BRCA1 CDKN1A CTNNB1
26 skeleton MP:0005390 9.77 BRCA1 BRCA2 CDKN1A CTNNB1 DPH1 EGFR
27 vision/eye MP:0005391 9.28 CDKN1A CTNNB1 DPH1 EGFR FOLR1 KRAS

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
CEA-Scan 17 Immunomedics Approved April 1996
2
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
3
Ethyol 17 AMIFOSTINE Alza Approved December 8, 1995
4
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
5
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
6
Lynparza 17 46 OLAPARIB AstraZeneca Approved December 2014

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 769)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
2
Ganirelix Approved Phase 4,Phase 3,Early Phase 1 123246-29-7, 124904-93-4 25081094
3
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
4
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
7
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Norethindrone Approved Phase 4,Phase 2,Phase 3,Early Phase 1 68-22-4 6230
11
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
12
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
14
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
15
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
17
Zinc Approved Phase 4,Early Phase 1 7440-66-6 32051 23994
18
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
19
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
20
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
21
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
22
Goserelin Approved Phase 4,Phase 3,Phase 2 65807-02-5 47725 5311128
23
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
24
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
25
Tranexamic Acid Approved Phase 4 1197-18-8 5526
26
Aprepitant Approved, Investigational Phase 4,Phase 2 170729-80-3 151165 6918365
27
Fosaprepitant Approved Phase 4,Phase 2 172673-20-0 219090
28
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2 53714-56-0 3911 657181
29
Menotropins Approved Phase 4,Phase 3,Phase 1,Phase 2 61489-71-2 5360545
30
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
31
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 616-91-1 12035
32
Danazol Approved Phase 4 17230-88-5 28417
33
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
34
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
35
Liraglutide Approved Phase 4 204656-20-2
36
Citalopram Approved Phase 4 59729-33-8 2771
37
Epinephrine Approved, Vet_approved Phase 4,Phase 3 51-43-4 5816
38 Moxonidine Approved Phase 4 75438-57-2 4810
39
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
40
Alogliptin Approved Phase 4 850649-61-5 11450633
41
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
42
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
43
Toremifene Approved, Investigational Phase 4,Phase 2,Phase 3 89778-26-7 3005573
44
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
46
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
47
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
48 Dienogest Approved Phase 4,Phase 2 65928-58-7
49
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2 71-58-9
50
Iron Approved Phase 4,Phase 2 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 2849)
id Name Status NCT ID Phase
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
2 Ovarian Tissue Freezing For Fertility Preservation Unknown status NCT00902720 Phase 4
3 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
5 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4
6 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
7 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4
8 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
9 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
10 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4
11 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4
12 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
13 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4
14 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4
15 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4
16 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4
17 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4
18 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
19 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4
20 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
21 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4
22 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4
23 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4
24 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4
25 Structured Exercise Training Program Versus Hypocaloric Hyperproteic Diet in Obese Anovulatory Infertile Patients With PCOS Completed NCT00473538 Phase 4
26 The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst Completed NCT00713778 Phase 4
27 A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve Completed NCT00746278 Phase 4
28 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
29 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4
30 Oral Contraceptive and Cardiovascular Risk in PCOS Completed NCT00593294 Phase 4
31 Second-Line Treatments for Anovulatory Infertility in PCOS Patients Completed NCT00558077 Phase 4
32 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4
33 Danazol Treatment in Endometriosis Women Before IVF Completed NCT01779232 Phase 4
34 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4
35 The Effect of Metformin on Different Hormones in PCOS Patients Completed NCT02568488 Phase 4
36 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
37 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4
38 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4
39 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4
40 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
41 hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4
42 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed NCT01999569 Phase 4
43 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
44 Pain Post Abdominal Laparoscopy Prevention With Arcoxia Completed NCT00565682 Phase 4
45 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
46 Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome Completed NCT00492882 Phase 4
47 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
48 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
49 Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
50 Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance Completed NCT00667498 Phase 4

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of Ovary 29
2 Ovarian Cancer 29
3 Ovarian Neoplasm 29

Anatomical Context for Ovarian Cancer

MalaCards organs/tissues related to Ovarian Cancer:

39
Breast, Ovary, Testes, Endothelial, Lung, Lymph Node, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

18
The Ovary

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 6342)
id Title Authors Year
1
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. ( 28089377 )
2017
2
lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. ( 27827314 )
2017
3
Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis. ( 28351334 )
2017
4
Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer. ( 28241454 )
2017
5
MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. ( 28086946 )
2017
6
MICU1 drives glycolysis and chemoresistance in ovarian cancer. ( 28530221 )
2017
7
Association of a common variant of SYNPO2 gene with increased risk of serous epithelial ovarian cancer. ( 28231729 )
2017
8
Individualized Medicine in Ovarian Cancer: Are We There Yet? ( 28089051 )
2017
9
Incidence and mortality trends of ovarian cancer in central Serbia. ( 28534377 )
2017
10
Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis. ( 28079805 )
2017
11
Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-I^ signaling. ( 28064471 )
2017
12
HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer. ( 28388957 )
2017
13
Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. ( 28521614 )
2017
14
Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. ( 28065618 )
2017
15
Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9. ( 28387653 )
2017
16
Long Noncoding RNA MIR4697HG Promotes Cell Growth and Metastasis in Human Ovarian Cancer. ( 28168162 )
2017
17
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells. ( 28350104 )
2017
18
Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer. ( 27908706 )
2017
19
Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. ( 28284216 )
2017
20
miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-I' in Ovarian Cancer OVCAR3 Cells. ( 28081739 )
2017
21
Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. ( 28205047 )
2017
22
TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. ( 28150354 )
2017
23
Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis. ( 28534018 )
2017
24
Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. ( 27721409 )
2017
25
An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing. ( 28525848 )
2017
26
Role of CYP1A1 in the biological activity of methylated resveratrol analogue, 3,4,5,4'-tetramethoxystilbene (DMU-212) in ovarian cancer A-2780 and non-cancerous HOSE cells. ( 28049037 )
2017
27
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1I+ and vascular endothelial growth factor. ( 28091613 )
2017
28
Bisphenol A and its derivatives tetrabromobisphenol A and tetrachlorobisphenol A induce apelin expression and secretion in ovarian cancer cells through a peroxisome proliferator-activated receptor gamma-dependent mechanism. ( 28111160 )
2017
29
Reduced Klotho expression contributes to poor survival rates in human patients with ovarian cancer, and overexpression of Klotho inhibits the progression of ovarian cancer partly via the inhibition of systemic inflammation in nude mice. ( 28259911 )
2017
30
Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer. ( 28524180 )
2017
31
Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. ( 28376831 )
2017
32
HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. ( 28039608 )
2017
33
Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells. ( 27737724 )
2017
34
Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer. ( 28129625 )
2017
35
The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer. ( 28209618 )
2017
36
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. ( 28528518 )
2017
37
Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. ( 28513088 )
2017
38
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. ( 28528917 )
2017
39
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. ( 28086243 )
2017
40
Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer. ( 28091920 )
2017
41
Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer. ( 27862665 )
2017
42
Dietary Quality and Ovarian Cancer Risk in African-American Women. ( 28535290 )
2017
43
Circadian Gene CLOCK Affects Drug-Resistant Gene Expression and Cell Proliferation in Ovarian Cancer SKOV3/DDP Cell Lines Through Autophagy. ( 28514207 )
2017
44
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. ( 28414925 )
2017
45
Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality? ( 28522108 )
2017
46
Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation. ( 28077793 )
2017
47
TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. ( 28148293 )
2017
48
VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients. ( 27780361 )
2017
49
Positron emission tomography in the management of documented or suspected recurrent ovarian cancer. ( 28089190 )
2017
50
Corrigendum to 'Equivalency challenge: evaluation of LipodoxAr as the generic equivalent for DoxilAr in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363]. ( 28089052 )
2017